HanchorBio, Inc. has priced its initial public offering at NT$120 per share ahead of its scheduled May 29 listing on Taiwan’s Innovation Board, marking one of the latest signs that global investors remain actively interested in next-generation immunotherapy developers despite a more selective biotech financing environment.
The Taiwan-based clinical-stage biotech company said its IPO attracted strong participation from both domestic and international institutional investors, with the offering oversubscribed during the bookbuilding process. The transaction also brought in OrbiMed as a strategic investor, highlighting continued overseas appetite for Asian biotechnology innovation and oncology-focused drug development platforms.
HanchorBio is developing immunotherapies targeting cancer and autoimmune diseases through its proprietary FBDB™ fusion protein platform, part of a broader industry movement toward engineered biologics designed to improve efficacy, safety, and targeting precision compared with earlier-generation immunotherapies.
The IPO represents an important milestone for Taiwan’s evolving biotechnology capital markets ecosystem, which has been working to attract more high-growth healthcare and deep-tech companies through the Innovation Board framework.
The company issued 9.4 million new common shares as part of the pre-listing capital increase, with roughly 8.46 million shares allocated through institutional bookbuilding. Cathay Securities served as lead underwriter.
The final IPO pricing landed in the middle of the indicative NT$110–130 range after institutional demand exceeded available allocations.
The strong investor response comes at a time when biotech financing markets remain uneven globally. While early-stage biotech fundraising has slowed in some Western markets because of higher interest rates and increased investor caution, companies with differentiated immunotherapy platforms and late-stage clinical potential continue attracting capital.
Cancer immunotherapy remains one of the pharmaceutical industry’s most competitive and strategically important sectors. Major pharmaceutical companies are actively seeking external innovation partnerships as several blockbuster oncology therapies approach future patent cliffs.
HanchorBio specifically pointed to the expected patent expirations surrounding Keytruda, one of the world’s best-selling oncology drugs developed by Merck & Co.. Analysts expect pharmaceutical companies to intensify acquisitions, licensing deals, and strategic partnerships targeting next-generation immuno-oncology assets over the coming decade.
The company’s focus on fusion protein engineering places it within a rapidly expanding area of biologics research aimed at improving immune system targeting while reducing toxicity and resistance challenges associated with earlier immunotherapies.
According to Evaluate Pharma and McKinsey & Company, global oncology drug spending is expected to continue rising sharply as precision medicine, cell therapy, antibody-drug conjugates, and engineered immunotherapies reshape cancer treatment pipelines worldwide.
The IPO also reflects broader trends in Asia’s biotech financing landscape. Taiwan, South Korea, Singapore, and China have all expanded policy initiatives and capital market reforms intended to strengthen regional biotechnology ecosystems and reduce reliance on Western funding centers.
OrbiMed’s participation is particularly notable because the healthcare investment firm has historically backed some of the biotechnology industry’s most prominent global companies across biopharmaceuticals, medical devices, diagnostics, and healthcare technology.
The investment may help strengthen HanchorBio’s credibility as it pursues additional pharmaceutical partnerships and global licensing discussions.
Following the IPO financing, HanchorBio said it now holds approximately US$140 million in cash and available credit facilities, providing funding support for clinical trials, manufacturing process development, and business development activities tied to its lead assets.
The company’s decision to release only about 6% of its listed share capital also reflects a more disciplined financing approach than some earlier biotech IPO cycles that prioritized aggressive capital raises at the expense of shareholder dilution.
Biotech investors have become increasingly focused on capital efficiency and clinical milestone execution following several years of volatile healthcare equity market performance.
Founded in 2020, HanchorBio has rapidly built an integrated biotechnology operating model covering early-stage research, process development, and clinical operations. The company’s international management structure and platform-based strategy position it within a growing class of Asian biotech firms seeking global commercialization opportunities rather than purely regional expansion.
For investors, the IPO highlights how immunotherapy innovation remains one of the healthcare sector’s most closely watched investment categories despite broader macroeconomic uncertainty.
The long-term success of companies like HanchorBio will likely depend on clinical trial execution, regulatory progress, partnership development, and the pharmaceutical industry’s ongoing search for next-generation oncology assets capable of replacing aging blockbuster therapies.
Market Landscape
Global biotechnology markets are increasingly prioritizing immunotherapy, precision medicine, and engineered biologics as pharmaceutical companies seek new growth drivers ahead of major patent expirations.
The oncology therapeutics market remains one of healthcare’s fastest-growing sectors, driven by rising cancer incidence, expanded biologics adoption, and advances in immune system engineering technologies.
At the same time, Asian biotech ecosystems are gaining greater international visibility as regional exchanges and governments strengthen funding support for innovative drug development companies and clinical research infrastructure.
Institutional investors are becoming more selective in biotech financing markets, favoring companies with differentiated technology platforms, strong balance sheets, and clear clinical development pathways.
Top Insights
- HanchorBio priced its Taiwan Innovation Board IPO at NT$120 per share after attracting strong institutional investor demand during the oversubscribed offering process.
- OrbiMed joined the transaction as a strategic investor, signaling continued international interest in Asian biotechnology and next-generation immunotherapy platforms.
- HanchorBio is developing oncology and autoimmune disease therapies using its proprietary FBDB™ fusion protein technology platform.
- Global pharmaceutical companies are increasingly seeking external immunotherapy innovation as major blockbuster oncology drugs approach future patent expirations.
- Taiwan’s Innovation Board continues emerging as a financing platform for biotechnology and deep-technology companies targeting international growth opportunities.
Get in touch with our fintech expert.
